Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity

Cancer Research

Volumn 61, Issue 16, 2001, Pages 6201-6212

  Sterman, Daniel H ^a   Wiewrodt, Rainer ^a   Kiefer, Michael ^a   Albelda, Steven M ^a   Odaka, Makoto ^a   Amin, Kunjlata M ^a   Kaiser, Larry R ^a   Zhang, Yi ^a   Gao, Guan Ping ^a   Wilson, James M ^a   Barsoum, James ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE THERAPY; GENE TRANSFER; IMMUNOSTIMULATION; MESOTHELIOMA; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAPERITONEAL; INTERFERON-BETA; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, SCID; PERITONEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0035881733     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Natural history and epidemiology of malignant mesothelioma
2. Advances in the treatment of malignant pleural mesothelioma
3. The European mesothelioma epidemic
4. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioama
5. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma
6. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma
7. Molecular pathobiology and immunology of malignant mesothelioma
8. Establishment of a murine model of malignant mesothelioma
9. Potential for interferon-α-based therapy in mesothelioma: Assessment in a murine model
10. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma
11. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12
12. Transforming growth factor-β: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma
13. Intrapleural administration of interleukin 2 in pleural mesothelioma: A Phase I-II study
14. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: A Phase II study
15. Intralesional cytokine therapy in cancer: A pilot study of GM-CSF infusion in mesothelioma
16. The interferon system
17. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons
18. Role of early cytokines, including α and β interferons (IFN-α/β), in innate and adaptive immune responses to viral infections
19. Interferon-β induces S phase accumulation selectively in human transformed cells
20. The combination of antiangiogenic agents to inhibit primary, tumor growth and metastasis
21. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas
22. Mechanism of interferon β-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines
23. In vitro effects of recombinant human interferon-γ on human mesothelial cells
24. Human malignant mesothelioma cell growth: Activation of Janus kinase 2 and signal transducer and activator of transcription I α for inhibition by interferon-γ
25. Effect of interferon-α2a on malignant mesothelioma
26. Recombinant interferon α2b in the treatment of diffuse malignant pleural mesothelioma
27. Phase II evaluation of recombinant interferon-β (IFN-βser) in patients with diffuse mesothelioma: A Southwest Oncology Group study
28. Intrapleural natural β interferon in the treatment of malignant pleural effusions
29. Activity of intrapleural recombinant γ-interferon in malignant mesothelioma
30. Intrapleural treatment with recombinant γ-interferon in early stage malignant pleural mesothelioma
31. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers
32. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN-β gene: Possible role of nitric oxide
33. Therapy of human ovarian cancer by transfection with the murine interferon-β gene: Role of macrophage-inducible nitric oxide synthase
34. Interferon (IFN)-β gene transfer into TS/A adenocarcinoma cells and comparison with IFN-α
35. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice
36. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon β gene therapy
37. Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse
38. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma
39. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: A Phase I trial (BB-IND 6274)
40. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene delivery in patients with localized malignancy: Results of a Phase I clinical trial in malignant mesothelioma
41. Humoral and cellular immune responses induced by adenoviral-based gene therapy for localized malignancy: Results of a Phase I clinical trial for malignant mesothelioma
42. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma
43. Cationic lipid: Bacterial DNA complexes elicit anti-tumor effects and adaptive immunity in murine intraperitoneal tumor models
44. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype
45. Adenoviral vectors
46. High throughput method for creating and screening recombinant adenoviruses
47. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system
48. Natural killer cells in antiviral defense: Function and regulation by innate cytokines
49. Action of spontaneously produced β interferon in differentiation of embryonal carcinoma cells through an autoinduction mechanism
50. Role of endogenous interferon-β in lipopolysaccharide-triggered activation of the inducible nitric-oxide synthase gene in a mouse macrophage cell line, J774
51. Characterization of early IL-12. 1FN-αβ, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection
52. Induction of bystander T cell proliferation by viruses and type I interferon in vivo
53. Type I interferons keep activated T cells alive
54. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo β-interferon
55. Interferon-β endogenously produced by intratumoral injection of cationic liposome-encapsulated gene: Cytocidal effect on glioma transplanted into nude mouse brain
56. IFN-β gene therapy induces systemic antitumor immunity against malignant glioma
57. Evaluation of immunogenicity of murine mesothelioma cells by immunization
58. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells
59. Peritoneal defences and peritoneum-associated lymphoid tissue
60. Antigen-presenting function of human peritoneum mesothelial cells
61. + cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis
62. Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination
63. Accessory role of human peritoneal mesothelial cells in antigen presentation and T-cell growth
64. Constitutive and inducible HLA antigen expression in malignant mesothelioma
65. Is cancer dangerous to the immune system?
66. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression